A new implant technology is offering hope to individuals suffering from advanced dry age-related macular degeneration (AMD), specifically a subtype known as geographic atrophy (GA). This innovative procedure, recently trialed at Moorfields Eye Hospital in London, involves the insertion of a tiny photovoltaic microchip behind the retina, allowing patients to regain some vision.
The trial, which included 38 participants from five European countries, focused on the Prima implant developed by California-based Science Corporation. Of the 32 patients who received the implant, 27 reported significant improvements in their ability to read using their central vision, showing an average improvement of five lines on an eye chart after one year.
Sheila Irvine, a 70-year-old blind patient, expressed her excitement about the procedure, stating that it has enabled her to read and engage in activities she once enjoyed, such as solving crosswords. Despite the challenges of using the device—requiring concentration and specific adjustments to read individual letters—she has experienced a remarkable turnaround in her quality of life.
Consultant ophthalmic surgeon Mahi Muqit, who led the UK trial, emphasized the significance of the implant, describing it as a pioneering advancement in providing meaningful vision for patients. While the Prima implant is currently not licensed for general use, there are hopes that it may soon be available to NHS patients.
Experts, including Dr. Peter Bloomfield from the Macular Society, view the developments as encouraging for those with limited treatment options. However, the trials are not designed to assist individuals with conditions affecting the optic nerve, which remains a critical limitation. The ongoing research highlights the potential for future applications of this technology in treating other visual impairments.